Skip to main content

SPINK9 Antibody [DyLight 405]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-45835V

Key Product Details

Species Reactivity

Human

Applications

ELISA, Immunohistochemistry

Label

DyLight 405 (Excitation = 400 nm, Emission = 420 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

serine peptidase inhibitor, Kazal type 9. (Uniprot# Q5DT21)

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for SPINK9 Antibody [DyLight 405]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: SPINK9

Alternate Names

LEKTI2, lymphoepithelial Kazal-type-related inhibitor 2, serine peptidase inhibitor, Kazal type 9, serine protease inhibitor Kazal type 9

Gene Symbol

SPINK9

Additional SPINK9 Products

Product Documents for SPINK9 Antibody [DyLight 405]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SPINK9 Antibody [DyLight 405]



DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...